Citrate Dialysate for Vascular Calcification

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Vascular Calcification+1 More
Citrate Dialysate - Device
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial will test whether dialysis with citrate can help slow the progression of vascular calcification.

Eligible Conditions
  • Vascular Calcification

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Baseline, Month 6, Month 12, Month 18, Month 24

Month 24
Change in rate of progression of breast arterial calcification (BAC)

Trial Safety

Trial Design

2 Treatment Groups

Standard Dialysate
1 of 2
Citrate Dialysate then Standard Dialysate
1 of 2

Active Control

Experimental Treatment

62 Total Participants · 2 Treatment Groups

Primary Treatment: Citrate Dialysate · No Placebo Group · N/A

Citrate Dialysate then Standard DialysateExperimental Group · 2 Interventions: Citrate Dialysate, Standard Dialysate · Intervention Types: Device, Device
Standard DialysateActiveComparator Group · 2 Interventions: Citrate Dialysate, Standard Dialysate · Intervention Types: Device, Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, month 6, month 12, month 18, month 24

Who is running the clinical trial?

Fresenius Medical Care Renal Therapies Group (FMCRTG)UNKNOWN
Emory UniversityLead Sponsor
1,502 Previous Clinical Trials
2,677,535 Total Patients Enrolled
W. Charles O'Neill, MDPrincipal InvestigatorEmory University

Eligibility Criteria

Age 18+ · Female Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: November 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.